Newsroom

RAHWAY, N.J.--(BUSINESS WIRE)--New data include Phase 3 subgroup analyses and patient-reported outcomes of investigational once-weekly oral combination of ISL/LEN....

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it executed an amendment to its Receivables Purchase Agreement (the “Receivables Sale Program”) on October 29, 2026. The amendment, among other things, extends the Scheduled Termination Date of the facility to October 2029, and the $150 million size of the Receivables Sale Program is unchanged. “We are pleased to have worked with our banking partner to extend the Receivables Sale Program until...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Capital Strength ESG Leaders UCITS ETF 30.10.2026 FCSG IE00BKPSPT20  650,002.00 USD  30,619,653.36   47.107  ...

MEDINA, Ohio--(BUSINESS WIRE)--RPM to Host Investor Day on November 9...

CHICAGO--(BUSINESS WIRE)--NIQ (NYSE: NIQ), a leading consumer intelligence company, today released its 2026 Environmental, Social and Governance (ESG) Progress Report, detailing the company’s progress on key ESG priorities throughout 2025. The report covers NIQ’s efforts across environmental responsibility, its people and communities, data integrity, and responsible AI. Key highlights from 2025 include: Strengthened its approach to climate risk and environmental measurement: NIQ conducted its f...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 30.10.2026 FXGB LN IE00BD5HBR05   79,467.00 GBP   1,713,923.71   28.893  ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of results from the investigator-sponsored, multicenter Phase 2 UNICORN trial evaluating short-course preoperative, or neoadjuvant, botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, alone or in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody, in patients with resectable, locally advanced colon cancer. The...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 30.10.2026 FTFX IE00BD5HBQ97   68,116.00 USD   1,944,880.53   28.552  ...

MIDDLETOWN, Pa.--(BUSINESS WIRE)--OpZira™, Inc., an ophthalmic medical device company advancing technologies for the detection and monitoring of ocular disease, today announced its subsidiary, AdaptDx, Inc., has completed its Stage II audit at the company's Lighthouse medical device manufacturing facility. The audit represents an important step in the ISO certification process and supports OpZira's plans to pursue CE marking for AdaptDx Pro® in the European Union in 2027.AdaptDx Pro is a portabl...

SAN MIGUEL DE ALLENDE, Mexico--(BUSINESS WIRE)--Sinda Ltd. (NYSE: SIND) (“Sinda” or the “Company”) today announced third quarter 2026 results and the filing of its Form 10-Q. “Sinda is laying the foundations for a world-class silver-gold mine, with the third quarter bringing excellent progress in drilling, exploration and site preparation,” said Daniel Muñiz, Sinda’s Executive Chairman. “Our priorities are clear: methodically and consistently take the project up the value chain, invest our capi...